Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis
By LabMedica International staff writers Posted on 13 Oct 2021 |

Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and several other entities of T-cell lymphoma.
A genetic analysis suggests that a rare blood cancer that affects immune T cells may be caused by exposure to smoking and aging-related mutations acquired during the early stage of production of new blood cells Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells.
Clinical Medical Laboratorians at Weill Cornell Medicine (New York, NY, USA) used next-generation genome sequencing to analyze 537 genes in 27 patients with AITL or PTCL for genetic changes that might lead to these T-cell tumors and to secondary cancers in some patients. All tissue samples (27 lymph node [LN] tissue specimens, 27 bone marrow [BM] aspirate/peripheral blood [PB] samples) were collected from 25 AITL or two PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019.
The tumor burden estimate was also based on more objective and sensitive immunophenotypic findings by flow cytometry). A 537-gene targeted sequencing panel, based on hybridization capture method for sequencing library construction and selection, was designed to investigate the genomic profile of the primary tumors and the BM/PB tissues. The NGS libraries were constructed using the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the probes from the customized Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA). Multiplexed libraries were sequenced using 150 bp paired end HiSeq 4000 sequencers (Illumina, San Diego, CA, USA). Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel.
The scientists reported that in about 70% of the patients, there were mutations in precursor cells, most likely stem cells, in the bone marrow that can lead to the production of growing numbers of blood cells with these mutations, as well as early development of the T-cell tumors. These mutations in the precursor cells have been thought to be related to aging. In addition, the team found that the mutations associated with the progression of these tumors might be linked to smoking or exposure to second-hand smoke. They also found that patients with a higher mutation burden of one of the genes associated with the early development of these tumors were at higher risk of developing additional types of tumors.
Wayne Tam, MD, PhD, a Professor of Pathology and Laboratory Medicine and senior author of the study, said, “Our results provide new information on how exposure to smoking may cooperate with early mutations in blood precursor cells to lead to the development of certain T-cell cancers. The findings suggest a potential new way to identify patients with AITL or PTCL who are most at risk of developing secondary tumors, and may also help scientists and clinicians improve how these cancers are prevented, diagnosed and treated.”
The authors concluded that they provided genetic evidence that AITL/PTCL-NOS, clonal hematopoiesis (CH), and concomitant hematologic neoplasms (CHN) can frequently arise from common mutated hematopoietic precursor clones. The study also suggests smoking exposure as a potential risk factor for AITL/PTCL-NOS progression. The study was published on September 28, 2021 in the journal eLife.
Related Links:
Weill Cornell Medicine
Roche
Twist Biosciences
Illumina
A genetic analysis suggests that a rare blood cancer that affects immune T cells may be caused by exposure to smoking and aging-related mutations acquired during the early stage of production of new blood cells Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells.
Clinical Medical Laboratorians at Weill Cornell Medicine (New York, NY, USA) used next-generation genome sequencing to analyze 537 genes in 27 patients with AITL or PTCL for genetic changes that might lead to these T-cell tumors and to secondary cancers in some patients. All tissue samples (27 lymph node [LN] tissue specimens, 27 bone marrow [BM] aspirate/peripheral blood [PB] samples) were collected from 25 AITL or two PTCL NOS patients who were diagnosed or confirmed from June 2010 to December 2019.
The tumor burden estimate was also based on more objective and sensitive immunophenotypic findings by flow cytometry). A 537-gene targeted sequencing panel, based on hybridization capture method for sequencing library construction and selection, was designed to investigate the genomic profile of the primary tumors and the BM/PB tissues. The NGS libraries were constructed using the KAPA Hyperplus Kit (Roche, Basel, Switzerland), and hybrid selection was performed with the probes from the customized Twist Library Prep Kit (Twist Biosciences, San Francisco, CA, USA). Multiplexed libraries were sequenced using 150 bp paired end HiSeq 4000 sequencers (Illumina, San Diego, CA, USA). Targeted enrichment of 45 genes recurrently mutated in myeloid malignancies was performed using the Thunderstorm system with a customized primer panel.
The scientists reported that in about 70% of the patients, there were mutations in precursor cells, most likely stem cells, in the bone marrow that can lead to the production of growing numbers of blood cells with these mutations, as well as early development of the T-cell tumors. These mutations in the precursor cells have been thought to be related to aging. In addition, the team found that the mutations associated with the progression of these tumors might be linked to smoking or exposure to second-hand smoke. They also found that patients with a higher mutation burden of one of the genes associated with the early development of these tumors were at higher risk of developing additional types of tumors.
Wayne Tam, MD, PhD, a Professor of Pathology and Laboratory Medicine and senior author of the study, said, “Our results provide new information on how exposure to smoking may cooperate with early mutations in blood precursor cells to lead to the development of certain T-cell cancers. The findings suggest a potential new way to identify patients with AITL or PTCL who are most at risk of developing secondary tumors, and may also help scientists and clinicians improve how these cancers are prevented, diagnosed and treated.”
The authors concluded that they provided genetic evidence that AITL/PTCL-NOS, clonal hematopoiesis (CH), and concomitant hematologic neoplasms (CHN) can frequently arise from common mutated hematopoietic precursor clones. The study also suggests smoking exposure as a potential risk factor for AITL/PTCL-NOS progression. The study was published on September 28, 2021 in the journal eLife.
Related Links:
Weill Cornell Medicine
Roche
Twist Biosciences
Illumina
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more